Mostrar el registro sencillo del ítem

dc.contributor.authorForman, John
dc.contributor.authorTaruscio, Domenica
dc.contributor.authorLlera, Virginia A
dc.contributor.authorBarrera, Luis A
dc.contributor.authorCoté, Timothy R
dc.contributor.authorEdfjäll, Catarina
dc.contributor.authorGavhed, Désirée
dc.contributor.authorHaffner, Marlene E
dc.contributor.authorNishimura, Yukiko
dc.contributor.authorPosada De la Paz, Manuel 
dc.contributor.authorTambuyzer, Erik
dc.contributor.authorGroft, Stephen C
dc.contributor.authorHenter, Jan-Inge
dc.contributor.authorInternational Conference for Rare Diseases and Orphan Drugs (ICORD)
dc.date.accessioned2023-03-09T09:29:48Z
dc.date.available2023-03-09T09:29:48Z
dc.date.issued2012-08
dc.identifier.citationActa Paediatr. 2012 Aug;101(8):805-7.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/15595
dc.description.abstractThere are more than 6000 rare diseases (defined as affecting <5/10 000 individuals in Europe, <200 000 people in the United States). The rarity can create problems including: difficulties in obtaining timely, accurate diagnoses; lack of experienced healthcare providers; useful, reliable and timely information may be hard to find; research activities are less common; developing new medicines may not be economically feasible; treatments are sometimes very expensive; and in developing countries, the problems are compounded by other resource limitations. Emphasis is required to support appropriate research and development leading to better prevention, diagnosis and treatments of rare diseases. Notably, clinical trials using already existing drugs may result in new, affordable, treatment strategies. Moreover, rare diseases may teach us about common disorders. Conclusions: Countries are encouraged to implement specific research and development activities within their individual capabilities, so that patients worldwide have equal access to necessary interventions to maximize the potential of every individual.es_ES
dc.language.isoenges_ES
dc.publisherWiley es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectOrphan drugses_ES
dc.subjectPublic healthes_ES
dc.subjectRare diseaseses_ES
dc.subject.meshBiomedical Research es_ES
dc.subject.meshGlobal Health es_ES
dc.subject.meshHealth Policy es_ES
dc.subject.meshHealth Services Accessibility es_ES
dc.subject.meshRare Diseases es_ES
dc.subject.meshClinical Trials as Topic es_ES
dc.subject.meshHumans es_ES
dc.subject.meshOrphan Drug Production es_ES
dc.subject.meshPatient Advocacy es_ES
dc.subject.meshPatient Rights es_ES
dc.titleThe need for worldwide policy and action plans for rare diseaseses_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID22519914es_ES
dc.format.volume101es_ES
dc.format.number8es_ES
dc.format.page805-7es_ES
dc.identifier.doi10.1111/j.1651-2227.2012.02705.xes_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1651-2227es_ES
dc.relation.publisherversionhttps://doi.org/10.1111/j.1651-2227.2012.02705.xes_ES
dc.identifier.journalActa paediatrica (Oslo, Norway : 1992)es_ES
dc.repisalud.centroISCIII::Instituto de Investigación de Enfermedades Rarases_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional